XLO
Xilio Therapeutics·NASDAQ
--
--(--)
--
--(--)
6.62 / 10
Outperform
Analyst consensus is a unanimous Buy, and fund‑flow scoring 7.7/10 is good. Small and medium investors show positive inflows, while large and extra‑large participants are net negative. Overall sentiment is outperformance, supporting a cautiously optimistic view.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-08-06
InstitutionLeerink Partners
Times predicted1
Historical Win Rate100.0%
What is the analyst consensus for XLO?
- XLO holds a Bullish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 6.62/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
